Zydus Cadila Begins Clinical Development of H1N1 Vaccine
Zydus Cadila, a pharmaceutical company based in Ahmedabad, Gujarat, India, will begin conducting trials for a H1N1 vaccine.
Zydus Cadila, a pharmaceutical company based in Ahmedabad, Gujarat, India, will begin conducting trials for an H1N1 vaccine following an approval by the Drug Controller General of India. The company says it is the first Indian company authorized to begin trials for the H1N1 vaccine.
The egg-based vaccine is expected to be available by April 2010. The company estimates that demand for the H1N1 vaccine in India will be 50–60 million does in the initial phase.
Zydus recently set up a vaccine technology center near its manufacturing center in Moraiya, Ahmedabad, India.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
